Mtx Ratiopharm (Methotrexate)

Methotrexate blocks dihydrofolate reductase, reducing the formation of tetrahydrofolate needed for DNA and RNA synthesis. This hampers the replication of rapidly dividing cells, including cancer cells and activated immune cells, thereby providing anti‑cancer and immunosuppressive effects.

The dosage of Mtx Ratiopharm is individualized by the prescribing healthcare professional based on the indication, patient weight, renal and hepatic function, and treatment response. Only a qualified prescriber should determine the appropriate dose and schedule.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in breast milk and affect the infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Methotrexate is a folate antagonist that directly interferes with DNA synthesis, whereas many other immunosuppressants, such as azathioprine or cyclosporine, act on different cellular pathways. Methotrexate is often preferred for its efficacy in rheumatoid and psoriatic arthritis and its oral or injectable formulations, but individual response and safety profiles guide therapy choice.

Mtx Ratiopharm should be stored at 2‑8 °C, kept refrigerated, protected from light, and not frozen or shaken. Maintaining the cold chain preserves drug stability and potency until the point of administration.

The product is supplied for injection and can be given via epidural, intra‑articular or intramuscular routes, depending on the therapeutic indication. Administration is performed by a qualified healthcare professional following aseptic technique and appropriate dosing guidelines.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, acute renal failure, and life‑threatening infections. Patients should be monitored regularly for liver enzymes, blood counts, renal function, and respiratory symptoms to detect these complications early.

Methotrexate is contraindicated in pregnant women, those planning pregnancy, and individuals with severe hepatic or renal impairment, uncontrolled infections, or known hypersensitivity to methotrexate. Caution is also advised for patients with pre‑existing blood dyscrasias or pulmonary disease.